Related Experiment Video
Updated: Jun 29, 2026
05:00
Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
Published on: April 1, 2019
Update on blepharospasm: report from the BEBRF International Workshop.
Mark Hallett1, Craig Evinger, Joseph Jankovic
1Human Motor Control Section, NINDS, NIH, 10 Center Drive MSC 1428, Bethesda, MD 20892-1428, USA. hallettm@ninds.nih.gov
Neurology
|October 15, 2008
Summary
This review covers blepharospasm, a focal dystonia. Research updates include pathology, pathophysiology, and treatments, with botulinum neurotoxin injections remaining the primary therapy.
Area of Science:
- Neurology
- Ophthalmology
Background:
- Blepharospasm is a focal dystonia affecting eyelid muscles.
- Understanding its clinical aspects, pathology, and pathophysiology is crucial.
- It must be differentiated from apraxia of eyelid opening.
Purpose of the Study:
- To provide an updated review of blepharospasm research.
- To cover diverse aspects including clinical presentation, underlying mechanisms, and therapeutic options.
Main Methods:
- Review of current literature on blepharospasm.
- Analysis of findings from imaging studies (e.g., MRI).
- Examination of physiological studies on neural plasticity and sensitization.
Main Results:
- New insights into blepharospasm pathology and pathophysiology.
- Evidence of increased plasticity and trigeminal sensitization.
- Botulinum neurotoxin injections remain the standard treatment.
Conclusions:
- Blepharospasm research is advancing, particularly in understanding its mechanisms.
- While current treatments are effective, novel therapies are emerging.
